These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35045942)

  • 21. [Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: 5-year results of the TARGET Ⅱ trial].
    Xu LJ; Gao Z; Song Y; Wang HH; Xu JJ; Gao LJ; Zhang Y; Song L; Zhao XY; Chen J; Yuan JQ; Qiao SB; Yang YJ; Xu B; Gao RL;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Jul; 46(7):523-528. PubMed ID: 30032542
    [No Abstract]   [Full Text] [Related]  

  • 22. Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: Final five-year results of the patient-level pooled analysis from the TARGET I and TARGET II trials.
    Li C; Guan C; Zhang R; Yang Y; Ma C; Li H; Chen S; Han Y; Xu B; Gao R;
    Catheter Cardiovasc Interv; 2019 Feb; 93(S1):818-824. PubMed ID: 30565397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Durable-Polymer Zotarolimus-Eluting and Biodegradable-Polymer Biolimus-Eluting Coronary Stents in Patients With Coronary Artery Disease: 3-Year Clinical Outcomes in the Randomized SORT OUT VI Trial.
    Raungaard B; Christiansen EH; Bøtker HE; Hansen HS; Ravkilde J; Thuesen L; Aarøe J; Villadsen AB; Terkelsen CJ; Krusell LR; Maeng M; Kristensen SD; Veien KT; Hansen KN; Junker A; Madsen M; Andersen SL; Jensen SE; Jensen LO;
    JACC Cardiovasc Interv; 2017 Feb; 10(3):255-264. PubMed ID: 28109874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1-Year Results of the REMEDEE Registry: Clinical Outcomes After Deployment of the Abluminal Sirolimus-Coated Bioengineered (Combo) Stent in a Multicenter, Prospective All-Comers Registry.
    Woudstra P; Kalkman DN; den Heijer P; Menown IB; Erglis A; Suryapranata H; Arkenbout KE; Iñiguez A; van 't Hof AW; Muller P; Tijssen JG; de Winter RJ
    JACC Cardiovasc Interv; 2016 Jun; 9(11):1127-34. PubMed ID: 27209254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent.
    Kirtane AJ; Leon MB; Ball MW; Bajwa HS; Sketch MH; Coleman PS; Stoler RC; Papadakos S; Cutlip DE; Mauri L; Kandzari DE;
    JACC Cardiovasc Interv; 2013 Apr; 6(4):325-33. PubMed ID: 23523453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two-year outcomes after treatment of severely calcified coronary lesions with the orbital atherectomy system and the impact of stent types: Insight from the ORBIT II trial.
    Généreux P; Bettinger N; Redfors B; Lee AC; Kim CY; Lee MS; Shlofmitz RA; Moses JW; Stone GW; Chambers JW
    Catheter Cardiovasc Interv; 2016 Sep; 88(3):369-77. PubMed ID: 27084293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term clinical outcomes with the next-generation Resolute Stent System: a report of the two-year follow-up from the RESOLUTE clinical trial.
    Meredith IT; Worthley SG; Whitbourn R; Walters D; McClean D; Ormiston J; Horrigan M; Wilkins GT; Hendriks R; Matsis P; Muller D; Cutlip DE
    EuroIntervention; 2010 Jan; 5(6):692-7. PubMed ID: 20142220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second-versus first-generation "Limus"-eluting stents in diabetic patients with coronary artery disease: a randomized comparison in setting of ISAR-TEST-4 trial.
    Kufner S; Byrne RA; Mehilli J; Massberg S; Birkmeier KA; Schulz S; Pache J; Schömig A; Kastrati A
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):E769-76. PubMed ID: 23754254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. COBRA PzF™ coronary stent in clinical and preclinical studies: setting the stage for new antithrombotic strategies?
    Cornelissen A; Sakamoto A; Sato Y; Kawakami R; Mori M; Kawai K; Kutyna M; Fernandez R; Ghosh S; Barakat M; Virmani R; Finn A
    Future Cardiol; 2022 Mar; 18(3):207-217. PubMed ID: 34521223
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcome after crush versus culotte stenting of coronary artery bifurcation lesions: the Nordic Stent Technique Study 36-month follow-up results.
    Kervinen K; Niemelä M; Romppanen H; Erglis A; Kumsars I; Maeng M; Holm NR; Lassen JF; Gunnes P; Stavnes S; Jensen JS; Galløe A; Narbute I; Sondore D; Christiansen EH; Ravkilde J; Steigen TK; Mannsverk J; Thayssen P; Hansen KN; Helqvist S; Vikman S; Wiseth R; Aarøe J; Jokelainen J; Thuesen L;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1160-5. PubMed ID: 24262616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Titanium-nitride-oxIde-coated stents multicenter registry in diaBEtic patienTs: the TIBET registry.
    Valdés Chavarri M; Bethencourt A; Pinar E; Gomez A; Portales JF; Pomar F; Calvo I; López-Minguez J; Valdesuso R; Moreu J; Martínez A; Nammas W
    Heart Vessels; 2012 Mar; 27(2):151-8. PubMed ID: 21448677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Small-vessel PCI outcomes in men, women, and minorities following platinum chromium everolimus-eluting stents: Insights from the pooled PLATINUM Diversity and PROMUS Element Plus Post-Approval studies.
    Guedeney P; Claessen BE; Mehran R; Kandzari DE; Aquino M; Davis S; Tamis L; Wang JC; Othman I; Gigliotti OS; Haghighat A; Singh S; Lopez M; Giugliano G; Horwitz PA; Sorrentino S; Underwood P; Allocco D; Meredith IT; Batchelor W
    Catheter Cardiovasc Interv; 2019 Jul; 94(1):82-90. PubMed ID: 30666784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes in unselected patients treated with the PROMUS Element platinum-chromium, everolimus-eluting stent: Final five-year results from the PE PROVE Study.
    Moreno R; Legrand V; Ferrario M; MacCarthy P; Redwood S; Werner N; Jung W; Ungi I; Zaman A; Richardt G; Crowley J; Schwimmbeck P; Christen T; Allocco DJ; Meredith IT
    Catheter Cardiovasc Interv; 2019 Feb; 93(3):398-403. PubMed ID: 30341836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of a biodegradable polymer Cobalt-Chromium sirolimus-eluting stent (EXCROSSAL) in treating de novo coronary artery disease: A pooled analysis of the CREDIT II and CREDIT III trials.
    Wang G; Wang H; Xu B; Yang Y; Yang Z; Li H; Zhang Z; Wang H; Yang L; Han Y
    Catheter Cardiovasc Interv; 2017 Mar; 89(S1):512-519. PubMed ID: 28112473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice).
    Smits PC; Vlachojannis GJ; McFadden EP; Royaards KJ; Wassing J; Joesoef KS; van Mieghem C; van de Ent M
    JACC Cardiovasc Interv; 2015 Aug; 8(9):1157-1165. PubMed ID: 26210806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcomes after percutaneous revascularization of complex coronary bifurcation lesions using a dedicated self-expanding biolimus-eluting stent system.
    Triantafyllis AS; Bennett J; Pagourelias E; McCutcheon K; Adriaenssens T; Sinnaeve PR; Desmet W; Dubois C
    Cardiol J; 2018; 25(4):470-478. PubMed ID: 29240962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Late-term safety and effectiveness of everolimus-eluting stents in chronic total coronary occlusion revascularization: Final 4-year results from the evaluation of the XIENCE coronary stent, Performance, and Technique in Chronic Total Occlusions (EXPERT CTO) multicenter trial.
    Kandzari DE; Karmpaliotis D; Kini AS; Moses JW; Tummala PE; Grantham JA; Orr C; Lombardi W; Nicholson WJ; Lembo NJ; Popma JJ; Wang J; Zhao W; McGreevy R
    Catheter Cardiovasc Interv; 2019 Oct; 94(4):509-515. PubMed ID: 31444897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.